BRD2 and neoplasm: Here, we presented an integrative proteogenomic characterization of 217 paired tumor/NAT samples with 7 years of prognosis information that exhibited a range of clinic-pathologic spectrum of this disease, extending and refining analytical opportunities provided by prior studies.